Aventis and Bayer call off joint venture plans

- Last updated on GMT

Related tags: Future, Medicine, Aventis

Franco-German drugmaker Aventis and Germany's Bayer have agreed not
to pursue their plans to create a joint venture in the field of
biological products.

Franco-German drugmaker Aventis and Germany's Bayer have agreed not to pursue their plans to create a joint venture in the field of biological products.

The two companies had intended to combine Aventis Behring, the therapeutic proteins business of Aventis, with the Biological products division of Bayer HealthCare. Both companies reviewed various possible forms of cooperation but a final agreement on the terms of the transaction could not be reached.

According to a statement this week Aventis is pro-actively exploring alternative options for the future of Aventis Behring.

In 2001, Aventis generated sales of € 17.7 billion and invested € 3 billion in research and development and employed.

Related news

Related products

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Flow Cytometry Services

Flow Cytometry Services

Q² Solutions | 01-Jun-2020 | Data Sheet

We are an established leader in flow cytometry services for clinical trials. Our technologies and solutions meet the growing global demand for enhanced...

Related suppliers

Follow us

Products

View more

Webinars